2 Reasons to Buy Johnson & Johnson Stock Like There's No Tomorrow

Johnson & Johnson spun off its consumer health business into Kenvue to focus on pharma and medtech; its top drug Stelara has lost exclusivity but management says that impact is now "in the rearview mirror" and the company still cites 28 platforms/products generating at least $1B each. Shares have climbed ~15% YTD; J&J pays an annual dividend of $5.20 (yield ~2.1%) with free cash flow cited as supporting continued dividend growth. The article frames J&J as a defensive, long-term buy despite not being included in Motley Fool Stock Advisor's current top-10 picks.

Analysis

Large-cap, diversified healthcare franchises trade less on single-product narratives and more on capital-allocation optionality; the prize is not only steady cash but the ability to redeploy that cash into higher-return, asset-heavy medtech tuck-ins or targeted R&D that compresses time-to-profitability for new platforms. Expect pressure on mid-cap medtech valuations over the next 12–24 months as strategic buyers with strong balance sheets buy growth at premiums to organic development costs.

A long-standing dividend anchor creates a stable shareholder base that compresses intraday volatility but also raises the bar for management to prove incremental uses of free cash flow — buybacks vs. dividends vs. bolt-on M&A will be the lever that moves the multiple. If management tilts toward buybacks, shares can re-rate even absent revenue surprises; if they accelerate M&A, watch short-term EPS dilution risk and announcement drift.

Key tail risks that would reverse the current constructive view are external: regulatory pricing reform, surprise large litigation outcomes, or concentrated supply-chain shocks to medtech subcomponents; any of these would hit free cash flow conversion and force a re-steering of capital priorities within 3–12 months. Conversely, positive catalysts are visible near-term readouts from late-stage assets and any credible announcement of disciplined M&A (tuck-ins < 1x revenue for medtech targets) that show immediate margin accretion within 12–18 months.

From a market-structure angle, the current sentiment premium for defensive healthcare can compress rapidly in a broad risk-on move; that makes entry timing important — prefer staggered accumulation and use hedges to preserve optionality if macro liquidity shifts unexpectedly in the next 1–3 quarters.

Key Decisions for Investors

• Core position: Buy JNJ on a 6–8 week stagger (scale-in over 3 tranches). Target 12–18 month total return of 10–15% (dividend + 6–10% price upside). Use a 12% stop or buy 18–24 month JNJ LEAPS as an alternative to accumulate convex upside.
• Yield enhancement: Purchase JNJ and sell 9–12 month covered calls ~5–7% OTM to capture 3–6% additional income. R/W: raises yield but caps upside to strike; suitable for funds targeting current income over maximal capital gain.
• Relative-value pair: Long JNJ / Short KVUE notional-neutral for 6–12 months. Thesis: quality cash-flow generative business should outperform the consumer health spin-off in a mixed macro environment. Target 8–15% relative outperformance; risk if consumer cyclical rebound re-rates KVUE.
• Tail protection: Buy 12-month JNJ puts ~10% OTM sized at 2–3% of portfolio value to cap downside beyond initial drawdowns. Cost is expected to be small insurance (1–3% of position) but provides asymmetric protection against regulatory or litigation shocks within 12 months.